Patients with polycythemia vera (PV) who received treatment with ruxolitinib achieved durable hematocrit control through week 80 and had improved symptom control at week 16 compared to those receiving the best available therapy, according to pooled results from the RESPONSE and RESPONSE-2 studies. Claire N. Harrison, DM, of Guy’s and St. Thomas’ NHS Foundation Trust, and colleagues presented the pooled analysis at the Twelfth Annual Meeting of the Society of Hematologic Oncology. The randomized, open-label phase III studies previously showed that “ruxolitinib demonstrated hematocrit control, complete hematologic response, and improved ...
Advertisement
Latest News
Learn what a team of researchers found about the impact of this practice.
Dr. Bose shared his insights at the Twelfth Annual Society of Hematologic Oncology Meeting in Houston.
A new study highlights the importance of effective management and close monitoring of GVHD.
Learn how nurses can educate their peers, their patients, and the public about blood cancers and their symptoms.
A study of more than 10,000 patients illuminated the characteristics and needs of patients who are in remission.
Approximately half of patients with gynecologic malignancies experience financial toxicity.
Learn how an innovative rehabilitation model improved clinical outcomes and patient satisfaction with nursing care.
Learn about the diverse unmet needs and potential solutions related to the experiences of patients and caregivers.
New research shows that major depressive disorder is associated with certain outcomes in this population of patients.
Nurses, nurse administrators, physician assistants, and oncologists/hematologists shared their insights with researchers.
Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, shares 3 key tips for nurses caring for these patients.
A subgroup analysis of CARTITUDE-4 evaluated ciltacabtagene autoleucel in functionally high-risk multiple myeloma.
Advertisement
Advertisement
Our Contributors
Theresa Brown, RNTheresa Brown, RN, is the New York Times best-selling author of "Healing" and "The Shift."
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®, is the owner of beyond Oncology Education, LLC.
Milagros Elia, MA, APRN, ANP-BCMilagros R. Elia, MA, APRN, ANP-BC, has 25+ years of oncology experience and is a highly regarded activist.
Pamela K. Ginex, EdD, MPH, RN, OCNPamela K. Ginex, EdD, MPH, RN, OCN, is an Assistant Professor at the Stony Brook University School of Nursing.
Teresa Hagan Thomas, PhD, RNTeresa Hagan Thomas, PhD, RN, is an Assistant Professor at the University of Pittsburgh School of Nursing.
Amanda Brink, DNP, APRN, FNP-BC, AOCNPAmanda Brink, DNP, APRN, FNP-BC, AOCNP, is an oncology nurse practitioner at the MD Anderson Cancer Center.
Alicia Michaelsen, BSN, RN, BMTCN®Alicia Michaelsen, BSN, RN, BMTCN®, is a nurse with over a decade of experience.
Fatemeh Youssefi, PhD, RN, OCNFatemeh Youssefi, PhD, RN, OCN, is a nurse who has specialized in oncology for the past 20 years.
Expert Interviews
Cancer Nursing Today delivers critical news and expert insights to support oncology nurses throughout their education and careers.
Sign up to receive Cancer Nursing Today eNewsletters:
Conference Highlights
Dr. Bose shared his insights at the Twelfth Annual Society of Hematologic Oncology Meeting in Houston.
A new study highlights the importance of effective management and close monitoring of GVHD.
A study of more than 10,000 patients illuminated the characteristics and needs of patients who are in remission.
Learn how an innovative rehabilitation model improved clinical outcomes and patient satisfaction with nursing care.
